Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome (Q39348241)

11 September 2017

title

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome (English)

1 reference

11 September 2017

0 references

Bifidobacterium infantis

object named as

Bifidobacterium infantis

1 reference

8

1 reference

11 September 2017

Peter J Whorwell

1

0 references

Duane Charbonneau

5

object named as

Duane Charbonneau

1 reference

11 September 2017

9

Eamonn M M Quigley

1 reference

11 September 2017

Linda Altringer

2

1 reference

11 September 2017

Jorge Morel

3

1 reference

11 September 2017

Yvonne Bond

4

1 reference

11 September 2017

Liam O'Mahony

6

1 reference

11 September 2017

Barry Kiely

7

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

The American Journal of Gastroenterology

11 September 2017

published in

1 reference

11 September 2017

volume

101

1 reference

11 September 2017

issue

7

1 reference

11 September 2017

page(s)

1581-1590

1 reference

Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Corticotropin releasing factor receptor antagonists: potential future therapy in gastroenterology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Serotoninergic neuroenteric modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

The use of probiotics in functional bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

From comic relief to real understanding; how intestinal gas causes symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2006.00734.X

10.1111/J.1572-0241.2006.00734.X

21 January 2018

Identifiers

DOI

1 reference

release_4ki4mvno6bcfxad4fpnrvbhkey

11 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4ki4mvno6bcfxad4fpnrvbhkey

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference